Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

A critical assessment of oxaprozin clinical profile in rheumatic diseases

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

image of Inflammopharmacology

Oxaprozin is a non-steroidal anti-inflammatory drug (NSAID) of the n-propionic acid class without potential for enantiomeric metabolism, used in the management of rheumatoid arthritis (RA), osteoarthritis (OA), musculoskeletal pain and other inflammatory conditions. Oxaprozin has been shown to be effective in a number of animal models of inflammation, pain and pyrexia and has subsequently been shown to be effective and well tolerated in the clinical management of signs and symptoms of adult rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, soft tissue disorders such as bursitis and tendonitis, and post-operative dental pain. The clinical efficacy of oxaprozin is well documented by a great number of clinical trials versus placebo and other NSAIDs. A metaanalysis was performed in order to evaluate the global clinical profile of oxaprozin. A total of 111 reports, articles and abstracts were collected, and 51 were included for analysis according to a predefined methodology. All included studies were double-blind and the majority had parallel arms except 4 which were cross-over. This meta-analysis demonstrated that oxaprozin, in the treatment of RA and OA, has at least equal or superior efficacy in comparison with placebo or standard doses of aspirin, diclofenac ibuprofen, indomethacin, nabumetone, naproxen, piroxicam and zomepirac, and is well tolerated. The meta-analysis confirms oxaprozin as a valid alternative in the treatment of rheumatic disorders.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
    Inflammopharmacology — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation